When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
Treatment of eosinophilic esophagitis can go beyond the use of proton pump inhibitors alone, Evan Dellon, MD, stated during his presentation at the ACG Postgraduate Course.
Treatment of eosinophilic esophagitis can go beyond the use of proton pump inhibitors alone, Evan Dellon, MD, stated during his presentation at the ACG Postgraduate Course.
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
Patients with eosinophilic esophagitis are at higher risk of developing a psychiatric disorder during the first 5 years after diagnosis, according to new research.
Patients with eosinophilic esophagitis are at higher risk of developing a psychiatric disorder during the first 5 years after diagnosis, according to new research.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
What type of food elimination treatment has demonstrated effectiveness among pediatric patients with eosinophilic esophagitis? Take our quiz and find out!
What type of food elimination treatment has demonstrated effectiveness among pediatric patients with eosinophilic esophagitis? Take our quiz and find out!
Do you know the dietary factors contributed the most to deaths from colorectal cancer in the G20 nations during 2021? Our quick quiz will answer that question!
Do you know the dietary factors contributed the most to deaths from colorectal cancer in the G20 nations during 2021? Our quick quiz will answer that question!
What comordid conditions put patients at risk of developing metabolic-dysfunction associated liver disease or steatohepatitis? Test your knowledge with our quick quiz!
What comordid conditions put patients at risk of developing metabolic-dysfunction associated liver disease or steatohepatitis? Test your knowledge with our quick quiz!
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
Patients with eosinophilic esophagitis are at higher risk of developing a psychiatric disorder during the first 5 years after diagnosis, according to new research.
Patients with eosinophilic esophagitis are at higher risk of developing a psychiatric disorder during the first 5 years after diagnosis, according to new research.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The findings underscore the substantial burden of steatotic liver disease and highlight the importance of recognizing its distinct subtypes in clinical practice.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
The study synthesizes data from 18 studies and more than half a million subjects to better characterize how nonbiologic factors contribute to MASLD burden.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
A new update from the US Multi-Society Task Force on Colorectal Cancer revises and refines recommendations for optimizing bowel preparation in colonoscopy.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
For practicing gastroenterologists, these results highlight the importance of proactive risk assessment and coordinated care strategies in MASLD populations, beyond liver-specific endpoints.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The study analyzed data from the Research Patient Data Registry between 2000 and 2023, focusing on patients aged 40 and older with a baseline FIB-4 score of 1.3 or higher.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.
The TEMPO trial enrolled 40,000 adults aged 50–74 years and randomly assigned them to one of eight groups, testing combinations of a planning tool and deadline prompts of varying lengths.